Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(04): 36-37
DOI: 10.1055/s-0041-1733192
Case Report

Prolonged Neutropenia Associated with Rituximab Therapy - A Case Report

R Rejiv
Department of Medical Oncology, Cancer Institute (W.I.A.) Adyar, Chennai-6000 020, India
,
S G Ramanan
Department of Medical Oncology, Cancer Institute (W.I.A.) Adyar, Chennai-6000 020, India
,
T G Sagar
Department of Medical Oncology, Cancer Institute (W.I.A.) Adyar, Chennai-6000 020, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chiuseric anti CD 20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four dose treatment program. J Clin Oncol 1998;16:2825-33
  • 2 Shimoni A, Hardan I, Yeshurun M, et al. Rituximab reduces relapse risk after allogenic and autologous stem cell transplantation in patients with high risk aggressive non Hodgkins lymphoma. Br J Haematology 2003;122:457- 64.
  • 3 Horwitz S, Negrin R, Blume K, Breslin S, Stuart M, et al. Rituximab as adjuvant to high dose therapy and autologous haemopoietic stem cell transplantation for aggressive non Hodgkins lymphoma. Blood 2003;138:357- 64.
  • 4 Davis TA, White CA, Grillo Lopez AJ, et al. Single agent monoclonal antibody efficacy in bulky non Hodgkins lymphoma: results of a phase II trial of Rituximab. J Clin Oncol 1999;17:1851-7.
  • 5 Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed onset neutropenia associated with rituximab therapy. Br J. Haematology 2003;121:913-8.
  • 6 Saikia T, Menon S, Advani S. Prolonged neutropenia following anti CD 20 therapy in a patient with relapsed follicular non Hodgkins lymphoma and corrected with IVIG. Ann Oncol 2001;12:1493-4.
  • 7 Voog K, Morschhauser F, Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-94.